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Abstract  
The aim of the present study was to evaluate the effect of two surfactants on in vitro permeation of 
butorphanol through equine nasal mucosa. Franz diffusion cells and equine nasal mucosa were used. 
Three formulations were developed based on citric acid, sodium citrate, sodium chloride, and 
butorphanol tartrate and administered at a 24.4 g cm-3 dose. Control formulation lacked any 
penetration enhancer. Formulation 1 (F1) had a cationic surfactant (cetrimonium bromide) and 
formulation 2 (F2) had a non-ionic surfactant (Tween 80). Statistically comparing flux values at the 
steady state (Jss), apparent permeability coefficient (Kp), and lag-time from control, F1 and F2 for the 
respiratory region does not show statistically significant differences (α= 0.05). However, statistically 
significant differences were found on the Jss and Kp, values from control, F1, and F2 in olfactory 
mucosa. A statistical analysis on the latter showed significant differences between the Jss values of 
F1 and F2 and between control and F2. Based on this, Tween 80 proved to be a promising excipient 
in developing intranasal butorphanol formulations in equines since it increases its passage through 
the nasal mucosa. These results are very promising to continue with the development of intranasal 
butorphanol formulation in equines. 
Keywords: butorphanol; development of intranasal formulation; equines; intranasal 
 
Resumen  
El objetivo del trabajo fue estudiar el efecto de dos surfactantes en la permeabilidad in vitro de 
butorfanol, a través de la mucosa nasal equina. Para ello se utilizaron celdas de difusión de Franz, 
mucosa nasal equina y fueron desarrolladas tres formulaciones basadas en ácido cítrico, citrato de 
sodio, cloruro de sodio y tartrato de butorfanol a la dosis de 24.4 g cm-3. La formulación control 
carecía de mejoradores de permeabilidad; la primera formulación (F1) contenía un surfactante 
catiónico (cetrimida) y la formulación 2 (F2) un surfactante no iónico (Tween 80). Al comparar 
estadísticamente los valores del flujo máximo en estado estacionario (Jss), coeficiente de 
permeabilidad aparente (Kp) y el tiempo lag provenientes de las mucosas nasales respiratorias de las 
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0.05). Sin embargo, cuando se compararon los valores de Jss y Kp provenientes de la mucosa nasal 
olfatoria de las formulaciones control, F1 y F2 sí se observaron. Tras realizar un análisis estadístico 
sobre estos últimos se descubrieron diferencias significativas entre los valores de Jss de F1 y F2 y 
entre control y F2. Basándonos en esto, se propone que el Tween 80 podría ser un excipiente 
promisorio en el desarrollo de formulaciones intranasales con aplicación equina, porque incrementa 
el pasaje del fármaco a través de la mucosa nasal equina. Estos resultados son prometedores para 
continuar en el desarrollo de formulaciones intranasales de butorfanol para uso en equinos. 
 Palabras clave: Butorfanol; desarrollo de formulación intranasal; equinos; intranasal. 
 
Resumo  
Este trabalho teve como objetivo estudar o efeito de dois surfactantes na permeabilidade in 
vitro de butorfanol através da mucosa nasal equina. Para isso, foram utilizadas células de difusão de 
Franz, mucosa nasal equina, e desenvolvidas três formulações com base em ácido cítrico, citrato de 
sódio, cloreto de sódio e tartarato de butorfanol na dose de 24,4 g cm-3. A formulação controle carecia 
de melhoradores de permeação; a primeira formulação (F1) continha um surfactante catiônico 
(cetrimida) e a formulação 2 (F2) um surfactante não iônico (Tween 80). Ao comparar 
estatisticamente os valores do fluxo máximo em estado estacionário (Jss), coeficiente de 
permeabilidade aparente (Kp) e o tempo lag (tlag) provenientes das mucosas nasais respiratórias das 
formulações controle, F1 e F2, não foram encontradas diferenças estatisticamente significativas (α= 
0.05). Entretanto, ao comparar os valores de Jss e Kp provenientes da mucosa nasal olfatória das 
formulações controle, F1 e F2, sim. Depois de realizar uma análise estatística sobre esses últimos, 
foram descobertas diferenças significativas entre os valores de Jss de F1 e F2, e entre o controle e F2. 
Com base nisso, propõe-se que o Tween 80 poderia ser um excipiente promissor no desenvolvimento 
de formulações intranasais com aplicação equina, já que amplia a passagem do fármaco através da 
mucosa nasal equina. Estes resultados são prometedores para avançar no desenvolvimento de 
formulações intranasais de butorfanol para uso em equinos.  




Butorphanol, a synthetic agonist-antagonist opioid, has become widely used in equine 
medicine for the management of pain (Matthews & Carroll, 2007). It is 3 to 7 times more 
potent than morphine, being commonly administered by intravenous route (Dale, et al., 2002; 
Ferreira, et. al, 2019).  
In veterinary medicine, intranasal administration of opioids would be an alternative 
route to intravenous, subcutaneous, oral or rectal administration. However, this 
administration route is not commonly used in horses except for local treatments. Intranasal 
administration has some suitable features becoming a potential choice for drugs whose site 
of action is inside the central nervous system. It is a painless and non-invasive, avoiding first-
pass metabolism. It seems also to be a favourable way to circumvent the blood brain barrier 
allowing the direct drug delivery to central nervous system (Dale, et al., 2002; Ferreira, et. 
al, 2019; Thorat, 2016). Moreover, it was demonstrated that intranasal administration is well 
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Nowadays, the development of intranasal formulations is a challenge. Nasal drug 
products contain therapeutically active ingredients dissolved in solutions or mixtures of 
excipients. There are various types of excipients used in nasal formulations, particularly 
surfactants because their incorporation into an intranasal formulation can modify the 
permeability of nasal membranes and then, facilitate the nasal absorption of drug (Thorat, 
2016). 
The aim of the present study was to compare in vitro permeation of butorphanol from 
two formulations with two different surfactants, cetrimonium bromide (a cationic surfactant) 





All constituents used were of analytical quality. All formulations were made in 
distilled water. Composition of the studied formulations is listed in table 1. Once prepared, 
formulations were kept in fridge until experiment, which was not more than 48 hours.  
 
Table 1  
Composition (%, w/v) of control, F1 and F2 for intranasal administration. Note: derived 
from research. 
 Quantity  (%, W/V) 
Ingredients (g) Control F 1 F 2 
Butorphanol tartrate 3  3  3  
Citric acid 0.330  0.330  0.330  
Trisodium citrate 0.640  0.640  0.730  
Sodium chloride 0.640  0.640  0.640  
Polyoxyethylene (20) sorbitan 
monoleate (Tween 80) 
- - 0.030  




In vitro permeation studies 
Nasal mucosa was harvested from three healthy equines obtained from Anatomic 
Pathology Service, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata. 
Within the first hour of animal death, nasal mucosa was carefully removed and immersed in 
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washed with fresh cold saline solution to detach remains of blood and cut in 4 cm2 squares. 
Pieces of olfactory and respiratory areas were mounted in Franz-type diffusion cells (Franz, 
1978) with the mucosa side uppermost. Diffusion area was 1.23 cm2, receptor compartment 
volume of saline 7.0 ml and volume of formulation into donor compartment 1.0 ml 
(corresponding to a butorphanol dose of 24.4 mg/cm2). 
During all the experiment, cells were thermostatted at 37 °C, stirred constantly with 
Teflon-coated magnetic bar and without light directly (Figure 1). Samples of 800 μl were 
collected hourly, over a 6 hour period, from the receptor compartment adding an equivalent 
amount of fresh saline solution to maintain a constant volume. Each set of experiments was 
performed six-fold. The samples were frozen at -20 °C for no longer than four weeks. After 
the assay the samples of mucosa were analysed to confirm their viability in Anatomic 
Pathology Service, Facultad de Ciencias Veterinarias, Universidad Nacional de La Plata. All 
animal experiments have been aproved by the Comisión Institucional para el Cuidado y Uso 
de Animales de Laboratorio (CICUAL), Facultad de Ciencias Veterinarias, Universidad 





Photograph of Franz-type diffusion cells. 1: donor chamber; 2: 
receptor chamber; 3: horse nasal mucosa; 4: Arm of donor 
compartment; 5: Arm of receptor compartment; 6: Magnetic 
stirrer station. Note: derived from research 
 
 
Measurement of butorphanol concentrations 
Butorphanol concentration was quantified using UV/Vis microplate 
spectrophotometer (Multiskan GO, Thermo Fisher Scientific) using a method previously 
validated (Velloso, et al. 2018). Butorphanol detection was carried out at 280 nm in UV-96-
well microplate. Calibration curves were established by loading eight-fold eight 
concentrations of butorphanol tartrate in a range of 1 - 100 μg ml-1. 
 
Data analysis 
Plot of the cumulative amount of butorphanol (μg/cm2) against time (h) were 
constructed per each Franz-type diffusion cell. The X-intercept of the extrapolated linear 
region gave the lag-time (h). The slope of the linear portion of the graph provided maximum 
flux values at the steady state (Jss, μg cm
-2 h-1) and apparent permeability coefficients (Kp, cm 
h-1) were calculated according to the equation: 
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Where Cd is the drug concentration in the donor compartment; it is assumed that under 
sink condition the drug concentration in the receptor compartment is negligible compared to 
that in the donor compartment. Furthermore, Jss, Kp and lag-time of each cell, were averaged 
and their standard deviation calculated. 
In all of cases, it was previously verified that the data met the assumption of 
independence, normality and homoscedasticity using Shapiro-Wilk test and Levene test. 
 Parameters obtained in each cell were statistically analyzed applying the software 
Statgraphics Centurion XVI.II. Analysis of variance (ANOVA) was used to compare values 
of Jss, Kp, and lag-time for control, F1 and F2 from olfactory and respiratory nasal mucosa. 
Comparison between respiratory and olfactory parameters was performed by applying 
Student-t test.  
 
Analysis and results  
Figure 2 shows the cumulative amount of butorphanol that permeated through horse 
olfactory and respiratory nasal mucosa for tested formulations. Mean (±SD) for flux, apparent 
permeability coefficients and lag-time for respiratory and olfactory mucosa from control, F1 




 In vitro penetration of butorphanol through equine nasal mucosa using Franz-type diffusion cells. 
There were used three formulations with butorphanol: F1 had CTAB, F2 contained Tween 80, and 
control formulation. Butorphanol tartrate was in a doses of 24.4 mg/cm2. Each point represents the 
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 Mean ± SD of butorphanol In vitro permeation parameters through horse nasal mucosa 
using Franz-type diffusion cells for the three tested formulations. 
Jss = flux at the steady state. Kp = apparent permeability coefficient. tlag = lag-time. Note: 







CONTROL F1 F2 
Jss  
(μg cm-2 h-1)  
Olfactory 1593.9 ± 137.89 1916.825 ± 599.85 3524.4 ± 369.5 
Respiratory 329.9 ± 45.8 205.45 ± 97.33 880.67 ± 706.99 
Kp (cm h-1) Olfactory 0.065 ± 0.006 0.079 ± 0.0246 0.1445 ± 0.015 
Respiratory 0.014 ± 0.002 0.008 ± 0.004 0.036 ± 0.029 
lag-time  (h) Olfactory -0.0117 ± 0.7 -0.581 ± 0.4033 -0.579 ± 0.161 
Respiratory -1.47 ± 0.3 -0.0576 ± 1.33 -0.371 ± 0.941 
 
Assumptions of normality were accepted for Jss from olfactory region and lag-time 
from both regions. It was not true for Jss and Kp from respiratory area, consequently the data 
was transformed with the following formula: (observed value+1)}. This transformation was 
accepted for respiratory Jss, but not for Kp from respiratory area. In this last case, it was 
necessary applied non-parametric Kruskal-Wallis test. Assumptions of homoscedasticity 
were true in all cases except lag-time from olfactory area. 
Comparison of Jss, Kp and lag-time from control, F1 and F2 for respiratory region do 
not show statistically significant differences (α= 0.05). However, statistically significant 
differences on the values of Jss and Kp from control, F1 and F2 in olfactory mucosa were 
observed (α =0.05). 
Multi-range test was applied over these data which showed statistically significant 
difference (α =0.05) and it was proved difference between Jss from control formulation and 
F2 formulation. Moreover, it was proved statistically significant difference between Jss from 
F1 and F2 (α =0.05). Also, significant difference (α =0.05) on Kp from olfactory area between 
control and F2 and between F1 and F2 were observed. 
 
Discussion 
Brain drug delivery is reduced by blood-brain-barrier, nevertheless, intranasal 
administration allows to avoid it, so the drug let into brain by direct and non-invasive path. 
This quality is profitable for the administration of drugs whose site of action is inside the 
central nervous system such as butorphanol (Velloso et al., 2019). Butorphanol is used in 
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fast, non-pain and bloodless administration without causing greater stress to the animal with 
higher bioavailability because intranasal administration, also avoid first-pass metabolism 
which affects butorphanol directly.  
Most of substances cross biological membranes through diffusion, a phenomena 
which is described by Fick Law (Haq et al., 2020) assuming that the velocity of transference 
per unit area (flux) of a membrane is a direct function of its thickness (Talevi & Bellera, 
2016, p 27), consequently is expected to butorphanol is more crossed through olfactory nasal 
mucosa than respiratory nasal mucosa, because the first is thinner than the second. 
On the other hand, it is reported that maximum flux values at the steady state (Jss) 
from F2 showed statistically significant difference from F1. As control, F1 and F2 have 
similar chemistry composition except for F1 and F2 had been added CTAB and Tween 80, 
respectively. It would be assumed that the observed differences reflect the presence of Tween 
80 in the F2. This result is backed up by Gao et al., (2019) who reported an in vivo assay 
where rats were administrated intranasal 2,3,5,6-tetramethylpyrazine using different kind of 
formulation with different surfactant’s concentration. It was demonstrated that the 
concentration of the drug inside the brain is significantly increased by Tween 80 (Gao et al., 
2019). 
Explicitly for butorphanol, it is anticipate that Jss value is statistically significant 
different with the added of surfactant inside the formulation. Butorphanol is a lipophilic drug 
whose logP (octanol-water) is 3.68 (Grassin-Delyle et al., 2012; Papich et al., 2009). 
Generally, formulations for intranasal administration need the presence of one or more 
excipients with solubilizing activity to increase the velocity of dissolution and the possibility 
of absorption which together became an improvement of its bioavailability (Vetter et al., 
2012). Developing formulation with surfactant whose aim is dissolve, emulsify, act as 
dispersant of suspensions or wetting agents can make changes in the biological membrane 
permeability which it is through or even, affecting their integrity (Tadros, 2014)  that it would 
explain Jss  obtained in this assay. 
Tween 80 is a hydrophilic non-ionic surfactant whose molecular formula is 
C58H124O26 widely used in medicinal and alimentary products (Prabhakar et al., 2013). Until 
now, the exact mechanism of action of Tween 80 remains unknown; however, it is accepted 
that is related to its chemical structure. Tween 80 is polyethylene chain with hydrophilic and 
hydrophobic characteristics, giving the ability of disorganize and dissolve intracellular lipids. 
Consequently it increases the fluency of cellular membranes from nasal mucosa. 
Furthermore, it was reported that Tween 80 is able to be placed between lipids and proteins 
in cellular membranes, disturbing and increasing the permeability of drugs; Tween 80 is 
linked to loss of tight junctions in tissues (Gao et al., 2019; Kaur & Mehta, 2017). Results 
obtained in our assay suggested that Tween 80 would be a promissory excipient during the 
development of butorphanol formulations for intranasal administration in equines because it 
would increase its bioavailability. On the other hand, it should consider that the choice of 
surfactant it would not be because an improvement in drug penetration, but also its low 
toxicity in long-term (Gao et al., 2019; Som et al., 2012). Som and collaborators (Som et al., 





Uniciencia. Vol. 35(2), e14784. July-December, 2021 Doi: https://dx.doi.org/10.15359/ru.35-2.1  
URL:  https://www.revistas.una.ac.cr/uniciencia  E-ISSN: 2215-3470 





is less than CMC from surfactant with charge. This fact is supported by the characteristic that 
non-ionic surfactant are less irritant and better tolerated than anionic and cationic surfactants.  
The lack of statistically significant differences between parameters Jss, Kp and lag-
time between F1 and control might be reflecting that the presence of CTAB in the formulation 
did not improve and even reduce butorphanol penetration through equine mucosa. 
CTAB is a cationic surfactant whose mechanism of action is linked to its ability of 
doing micelles with lipids from cellular membrane, which break the cellula (Cárdenas, 2016). 
As the efficacy of the most of penetration enhancers depends on their concentration (Haq et 
al., 2020), initially it is proposed that the used concentration of CTAB in this study was under 
the effective concentration for enhancing butorphanol penetration through equine nasal 
mucosa.  
Chakraborty and collaborators (Cárdenas, 2016), studied the effect of carvediol 
dissolution, a hydrophilic drug used in heart failure treatment, with presence of different 
surfactant with widely range of concentration and pH, showing that solubility was higher 
with the increase of CTAB concentration in all range of pH used, peaking at pH 3. 
Unfortunately in our study, the pH was fixed at 4.5, therefore it could affected the penetration.  
Our laboratory group had done previous in vivo studies where our control formulation 
was applied by intranasal administration (Ferreira et al. 2019) that showed our control 
formulation, had T½ abs of 0.426 ± 0.320 h with a bioavailability of 54.45 ± 20.09 %. From 
the results obtained in this in vitro test, it is expected that in vivo administration of F2 
formulation would lead to a significant increase in bioavailability. These results are very 




It is proposed that Tween 80 could be a promising excipient in the development of 
intranasal butorphanol formulations for using in equines because it would increase its passage 
through the nasal mucosa. Based on these data, it is expected to continue with the 
development on intranasal butorphanol formulations in equines. 
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